摘要
目的:探讨程序性死亡因子(PD-1)/程序性死亡因子配体1(PD-L1)免疫检查点抑制剂联合化疗治疗非小细胞肺癌(non-small cell lung cancer,NSCLC)的临床效果。方法:选取2015年6月-2017年6月本院收治的84例NSCLC患者,根据随机数字表法将其分为观察组和对照组,每组42例。对照组采用顺铂联合吉西他滨治疗,观察组在对照组的基础上加用帕博利珠单抗。比较两组治疗效果、生存情况及毒副反应发生情况。结果:观察组治疗总有效率为85.71%,高于对照组的59.52%,差异有统计学意义(P<0.05)。观察组随访1、2、3年的生存率分别为90.48%、66.67%、47.62%,均高于对照组的57.14%、42.86%、16.67%,差异均有统计学意义(P<0.05)。观察组毒副反应发生率为9.52%,低于对照组28.57%,差异有统计学意义(P<0.05)。结论:NSCLC患者治疗方案采用PD-1/PD-L1免疫检查点抑制剂联合化疗能够增强治疗效果,生存率高,不良反应较少,预后更好。
Objective:To investigate the clinical application effect of programmed death factor (PD-1)/programmed death factor ligand 1 (PD-L1) immune checkpoint inhibitor combined with chemotherapy in the treatment of non-small cell lung cancer (NSCLC).Method:A total of 84 NSCLC patients admitted to our hospital from June 2015 to June 2017 were selected,and they were divided into observation group and control group according to the random number table method,42 cases in each group.The control group was treated with Cisplatin combined with Gemcitabine,and the observation group was treated with Pembrolizumab on the basis of the control group.The therapeutic effect,survival situation and the occurrence of toxic reactions were compared between two groups.Result:The total effective rate of the observation group was 85.71%,which was higher than 59.52% of the control group,the difference was statistically significant (P<0.05).The survival rates of the observation group after 1,2 and 3 years of follow-up were 90.48%,66.67% and 47.62%,respectively,which were higher than 57.14%,42.86% and 16.67% of the control group,the differences were statistically significant (P<0.05).The occurrence of toxic reactions of the observation group was 9.52%,which was lower than 28.57% of the control group,the difference was statistically significant (P<0.05).Conclusion:The treatment of NSCLC patients with PD-1/PD-L1 immune checkpoint inhibitor combined with chemotherapy can enhance the therapeutic effect,with a high survival rate,fewer adverse reactions and better prognosis.
作者
蒋轶
王志
左宏波
JIANG Yi;WANG Zhi;ZUO Hongbo(The First People’s Hospital of Jiujiang City,Jiujiang 332000,China)
出处
《中国医学创新》
CAS
2021年第24期51-54,共4页
Medical Innovation of China
基金
九江市科技计划项目(2017101)。
关键词
非小细胞肺癌
程序性死亡因子
程序性死亡因子配体1
免疫检查点抑制剂
化疗
Non-small cell lung cancer
Programmed death factor
Programmed death factor ligand 1
Immune checkpoint inhibitor
Chemotherapy
